Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS)
Neuren Pharmaceuticals (ASX: NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS). Read the full press release here. Highlights: Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement from baseline after 13 weeks that was statistically significant (Wilcoxon signed […]